Montelukast pharmacokinetics in cystic fibrosis.

Objectives: To determine if patients with cystic fibrosis (CF) have an altered pharmacokinetic profile of montelukast, we studied the single-dose pharmacokinetics in 12 patients with CF and 12 age- and gender-matched controls after they received a 10-mg oral dose.

Methods: Plasma samples were collected before dosing and at 0.5, 1, 1.